Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Related Questions
Is it still significant to denote the etiology of ILD in a patient with PPF?
What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?
How often are you performing CT screening in CVID patients to screen for ILD?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
What is your approach to treatment in a patient with radiographic UIP but pathologic evidence of both fibrotic NSIP and UIP?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
What is your approach to evaluating amiodarone induced interstitial pneumonitis?
What is your approach to managing rash associated with pirfenidone? Under what circumstances should the medication be temporarily held versus permanently discontinued?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
